
Test identifies patients who benefit from targeted cancer drugs
USA - A new laboratory test - EGFRx, developed by the Weisenthal Cancer Group* - has accurately identified patients who would benefit from treatment with the molecularly-targeted anti-cancer therapies gefitinib (Iressa, AstraZeneca) and erlotinib (Tarceva, Genentech), according to clinical data published at the annual meeting of the American Society of Clinical Oncology (ASCO).